Seven Fleet Capital Management LP reduced its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 75.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,066 shares of the company’s stock after selling 707,472 shares during the period. Seven Fleet Capital Management LP owned about 0.13% of Compass Therapeutics worth $510,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in CMPX. BlackRock Inc. acquired a new position in Compass Therapeutics during the 2nd quarter worth approximately $24,707,000. Palo Alto Investors LP acquired a new stake in Compass Therapeutics in the second quarter valued at approximately $12,771,670. Vivo Capital LLC boosted its position in Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after buying an additional 3,502,000 shares in the last quarter. BVF Inc. IL grew its stake in shares of Compass Therapeutics by 63.5% during the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock worth $41,697,000 after buying an additional 3,014,842 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in shares of Compass Therapeutics during the third quarter worth $9,892,000. 68.43% of the stock is owned by institutional investors.
Compass Therapeutics Stock Performance
Shares of NASDAQ:CMPX opened at $2.38 on Friday. Compass Therapeutics, Inc. has a 52 week low of $1.61 and a 52 week high of $6.88. The firm has a market cap of $428.61 million, a PE ratio of -5.95 and a beta of 0.95. The firm’s fifty day moving average is $2.22 and its 200-day moving average is $3.32.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on CMPX shares. Stifel Nicolaus set a $6.00 price target on Compass Therapeutics in a research note on Monday, June 1st. Wall Street Zen lowered Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 8th. Piper Sandler upped their target price on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. LADENBURG THALM/SH SH assumed coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They issued a “buy” rating and a $5.00 target price for the company. Finally, Citigroup reissued a “market outperform” rating on shares of Compass Therapeutics in a research note on Thursday, June 4th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Compass Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $11.77.
Check Out Our Latest Stock Analysis on CMPX
About Compass Therapeutics
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Recommended Stories
- Five stocks we like better than Compass Therapeutics
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
